Lignocaine-Dexamethasone Combination Shows Superior Efficacy in Preventing Propofol Injection Pain

Could This New Combination Therapy Revolutionize Propofol Pain Management?

A recent clinical trial has demonstrated that combining intravenous lignocaine and dexamethasone significantly reduces propofol-induced injection pain compared to either agent used alone, potentially offering anesthesiologists a more effective approach to improving patient comfort during anesthetic induction. The study, which enrolled 90 adult patients scheduled for elective surgeries under general anesthesia, provides new evidence for a synergistic effect between these commonly available medications in addressing one of the most frequent complaints associated with propofol administration.

Propofol remains the intravenous anesthetic of choice for many clinicians due to its rapid onset, short duration of action, and favorable pharmacokinetic profile. However, the drug is notorious for causing pain during injection, with incidence rates reported between 30-70% of patients. This pain, while temporary, can significantly impact patient satisfaction and increase perioperative anxiety, particularly in first-time surgical patients. The mechanism behind propofol-induced pain is multifactorial, involving direct irritation of the venous endothelium and activation of the kallikrein-kinin system, which triggers bradykinin release, increases vascular permeability, and sensitizes nerve endings to nociceptive transmission. Additional factors that can influence pain severity include vein size, injection rate, and the temperature of the propofol emulsion. Given these complex mechanisms, researchers have long sought effective preventive strategies that preserve propofol's beneficial pharmacological properties while mitigating its painful administration. Various pharmacological agents have been investigated for this purpose, including opioids, NSAIDs, magnesium sulfate, ketamine, and local anesthetics, with lignocaine emerging as the most consistently effective option through its inhibition of voltage-gated sodium channels and disruption of action potential transmission.

How Was the Clinical Trial Structured?

The randomized controlled trial divided participants into three equal groups of 30 patients each: Group A received 40 mg of intravenous lignocaine (2 mL of 2%), Group B received 8 mg of intravenous dexamethasone (2 mL), and Group C received a combination of both agents (40 mg lignocaine + 8 mg dexamethasone). All pretreatments were administered via a 20G intravenous cannula placed in the dorsum of the hand, 60 seconds before propofol injection. After standard monitoring was established and baseline vital signs recorded, each patient received their assigned pretreatment over 10 seconds. One minute later, 2 mL of propofol (1% solution) was injected over 5 seconds, followed by the remaining induction dose titrated according to patient response. Pain assessment was conducted immediately after the initial 2 mL propofol bolus using a Verbal Rating Scale (VRS), with scores ranging from 0 (no pain) to 3 (severe pain). The assessment was performed by an anesthesiologist who was blinded to group allocation, enhancing the objectivity of the results. Data analysis was conducted using SPSS version 26.0, with categorical variables expressed as frequencies and percentages, and continuous variables as mean ± standard deviation. The Chi-square test was used for intergroup comparisons of pain incidence, while one-way ANOVA followed by Tukey's post hoc test was applied for comparing mean pain scores among groups, with a p-value < 0.05 considered statistically significant.

What Are the Key Outcomes of the Study?

The study findings revealed striking differences in pain experiences across the three treatment groups. Group C (combination therapy) exhibited the lowest incidence and severity of pain, while Group A (lignocaine alone) had the highest frequency of moderate and severe pain. Statistical analysis confirmed that pain incidence was significantly reduced in the combination group compared to both individual agent groups (p < 0.001). Post-hoc analysis further demonstrated that mean pain scores were significantly lower in Group C than in either Group A or B (p < 0.05). The demographic and baseline clinical characteristics were comparable across all three groups, with no statistically significant differences in age, gender, or body mass index (BMI), confirming the homogeneity of the study population. Importantly, the researchers reported no major adverse effects in any treatment group, with minor issues such as transient flushing or localized discomfort occurring rarely and being evenly distributed across all groups. These safety findings align with the established safety profiles of both lignocaine and dexamethasone at the therapeutic doses used in the study, suggesting that the combination approach does not introduce new safety concerns while providing enhanced analgesic efficacy.

Why Does the Combination Approach Work?

The results support a synergistic mechanism between lignocaine and dexamethasone in preventing propofol-induced pain. Lignocaine, an amide-type local anesthetic, works primarily by inhibiting voltage-gated sodium channels in neuronal cell membranes, thereby preventing the formation and conduction of nerve impulses. This mechanism provides rapid local analgesia at the injection site. Dexamethasone, a potent synthetic corticosteroid with anti-inflammatory and membrane-stabilizing properties, likely contributes by reducing local inflammation, stabilizing vascular permeability, and providing endothelial protection. When combined, these complementary mechanisms appear to provide more comprehensive prevention of pain than either agent alone can achieve. The lignocaine component offers immediate neural blockade, while the dexamethasone component may extend and strengthen this analgesic effect through modulation of inflammatory mediators, addressing multiple aspects of the propofol-induced pain response simultaneously. This dual-mechanism approach represents a potentially valuable advancement in perioperative pain management strategies, targeting both nociceptive and inflammatory pathways involved in propofol-induced discomfort.

How Might These Findings Transform Clinical Practice?

The clinical implications of these findings are significant for anesthetic practice. Propofol induction is a critical moment in the patient's perioperative journey, and discomfort during this phase can negatively influence the overall anesthetic experience. By implementing a simple, effective strategy to reduce injection pain, anesthesiologists may improve patient satisfaction, decrease perioperative anxiety, and potentially reduce the need for additional anxiolytics or sedatives. The combination of lignocaine and dexamethasone offers an accessible solution using medications that are already widely available in operating rooms worldwide. Additionally, dexamethasone's established antiemetic properties may provide the added benefit of reducing postoperative nausea and vomiting, further enhancing the quality of the perioperative experience. For clinical research coordinators and investigators, this study demonstrates how relatively simple interventions combining existing medications can meaningfully impact patient comfort without introducing new risks or significantly altering established protocols. The ease of administration and favorable safety profile make this combination approach particularly attractive for routine clinical implementation in diverse surgical settings.

What Are the Limitations and Future Research Directions?

Despite these promising results, several limitations should be considered when interpreting the study findings. The research was conducted at a single center with a relatively modest sample size of 90 patients, which may limit the generalizability of the results to broader patient populations or different clinical settings. Additionally, pain assessment relied on subjective reporting using the Verbal Rating Scale, which, while clinically accepted, can be influenced by individual factors such as pain tolerance, anxiety levels, and previous surgical experiences. Future research directions might include larger multicenter trials to validate these findings across diverse patient populations, incorporation of objective biomarkers for pain assessment to complement subjective reporting, and further investigation into the mechanistic underpinnings of the observed synergistic effect. The combination of lignocaine and dexamethasone might also be evaluated against other propofol pain prevention strategies to establish comparative efficacy and determine optimal protocols for different clinical scenarios. Could this combination approach become the new standard of care for propofol administration, and what barriers might exist to its widespread implementation in various healthcare settings?

In conclusion, this study provides compelling evidence that the combination of intravenous lignocaine and dexamethasone offers superior efficacy in reducing propofol-induced injection pain compared to either agent used alone. The synergistic approach appears safe, effective, and straightforward to implement in clinical practice, potentially offering a valuable improvement to current anesthetic protocols. For anesthesiologists, clinical researchers, and other perioperative professionals, these findings present an opportunity to enhance patient comfort during a common but potentially distressing aspect of anesthetic care. How might this evidence influence your approach to propofol administration in your clinical practice, and what additional research questions does this study raise about optimizing the perioperative experience for patients undergoing general anesthesia?

Summary

A randomized controlled trial involving 90 adult surgical patients has demonstrated that combining intravenous lignocaine (40 mg) with dexamethasone (8 mg) significantly reduces propofol-induced injection pain compared to either medication used alone. Propofol, while widely used for anesthetic induction due to its favorable pharmacokinetic profile, causes pain during injection in 30-70% of patients through mechanisms involving venous endothelium irritation and kallikrein-kinin system activation. The study divided participants into three groups receiving lignocaine alone, dexamethasone alone, or the combination, with pain assessed using a Verbal Rating Scale immediately after propofol injection. Results showed the combination therapy group experienced the lowest incidence and severity of pain, with statistically significant reductions compared to single-agent groups. The synergistic effect likely results from lignocaine's rapid neural blockade through sodium channel inhibition combined with dexamethasone's anti-inflammatory and membrane-stabilizing properties. No major adverse effects were reported in any group, suggesting the combination approach is safe while providing enhanced analgesic efficacy. These findings have significant clinical implications, as this simple intervention using readily available medications could improve patient satisfaction, reduce perioperative anxiety, and potentially decrease the need for additional sedatives. The study's limitations include its single-center design, modest sample size, and reliance on subjective pain assessment, suggesting the need for larger multicenter trials to validate these findings across diverse patient populations and clinical settings.